HELP
Cybin Inc. Common StockNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$202.07M
P/E Ratio
—
EPS
$-4.30
Beta
0.70
52W High
$9.83
52W Low
$3.76
50-Day MA
$4.94
200-Day MA
$6.06
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Cybin Inc. Common Stock
Cybin Inc., doing business as Helus Pharma, a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company is headquartered in Toronto, Canada.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-119.25M |
| Operating Margin | 0.00% |
| Return on Equity | -55.90% |
| Return on Assets | -32.00% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.05 |
| Price-to-Book | 0.74 |
| Price-to-Sales (TTM) | 16436.36 |
| EV/Revenue | 11762.75 |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $49.89M |
| Float | $101.59M |
| % Insiders | 3.71% |
| % Institutions | 53.90% |
Historical Volatility
HV 10-Day
69.75%
HV 20-Day
70.49%
HV 30-Day
63.80%
HV 60-Day
73.51%
HV Rank
—
Volatility is currently expanding
Analyst Ratings
Consensus ($43.02 target)
9
BuyMore HEALTHCARE Stocks
Data last updated: 6/13/2026